Human Oncology & Pathogenesis Program

The Emily Cheng Lab

Research

Emily H. Cheng, MD, PhD
Emily H. Cheng, MD, PhD
Attending Pathologist, Department of Pathology; Member, Human Oncology and Pathogenesis Program

Professor

The focus of the Cheng laboratory is to elucidate the molecular mechanisms of cell death with an overarching goal of directly translating cell death mechanisms into novel anti-cancer therapeutic strategies that can effectively trigger cancer cell death and enhance anti-cancer immunity.

View Lab Overview

The Cheng Lab

The Cheng Lab

Publications Highlights

Xie Y, Sahin M, Sinha S, Wang Y, Nargund AM, Lyu Y, Han S, Dong Y, Hsieh JJ, Leslie CS, Cheng EH. SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes. Nat Cancer. 2022 Feb 3. doi: 10.1038/s43018-021-00316-3. Epub ahead of print.

Tanaka K, Yu HA, Yang S, Han S, Selcuklu SD, Kim K, Ramani S, Ganesan YT, Moyer A, Sinha S, Xie Y, Ishizawa K, Osmanbeyoglu HU, Lyu Y, Roper N, Guha U, Rudin CM, Kris MG, Hsieh JJ, Cheng EH. Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis. Cancer Cell. 2021 Sep 13;39(9):1245-1261.e6. doi: 10.1016/j.ccell.2021.07.006. Epub 2021 Aug 12. PMCID: PMC8440494.

Ren D, Tu H, Kim H, Wang GX, Bean GR, Takeuchi O, Jeffers JR, Zambetti GP, Hsieh JJD, Cheng EHY. BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. Science. 2010 Dec 3;330(6009):1390-3. doi: 10.1126/science.1190217.

Kim H, Rafiuddin-Shah M, Tu HC, Jeffers J, Zambetti GP, Hsieh JJD, Cheng EHY. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol. 2006 Dec;8(12):1348-58. Epub 2006 Nov 19.

Kim H, Tu H, Ren D, Takeuchi O, Jeffers JR, Zambetti GP, Hsieh JJD, Cheng EHY. Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. Mol Cell. 2009 Nov 13;36(3):487-99. doi: 10.1016/j.molcel.2009.09.030.

View All Publications

People

Emily H. Cheng, MD, PhD

Emily H. Cheng, MD, PhD

Attending Pathologist, Department of Pathology; Member, Human Oncology and Pathogenesis Program

Professor

  • Physician-scientist Emily Cheng studies the molecular mechanisms of cell death and their implications in tumorigenesis, tumor-microenvironment interactions, targeted therapy, and immunotherapy.
  • MD, Taipei Medical University
  • PhD, Johns Hopkins University School of Medicine
chenge1@mskcc.org
Email Address
646-888-3258
Office Phone

Members

Sohag Chakraborty
Research Fellow
Chih-Yu Chen
Research Technician
Hsuan-Ming Chi
Senior Research Technician
Prachi Gupta
Research Associate
Amrita Mangalvedhekar
Senior Research Scientist
Nobuhiro Tanno
Research Fellow
Shaoyuan Yang
Research Fellow
Gregory Bean
Gregory Bean
Graduate Research Assistant
Po Chan
Po Chan
Research Technician
Hui-Chen Chen
Research Fellow
Beatrice D'Orsi
Research Fellow
Song Han
Research Assistant
Yafen Huang, PhD
Yafen Huang
Research Fellow
Paul Jeng
Graduate Student
Chung Ping Liao, PhD
Chung Ping Liao
Research Fellow
Yogesh Tengarai Ganesan
Research Technician
Gary Wang
Gary Wang
Graduate Research Assistant
Akane Yamauchi
Research Fellow
Kota Ishizawa
Research Fellow
Kai Xi Lin
Research Technician
Allison Moyer
Shriram Ramani
Research Technician
Danielle Richards
Program Assistant
Sonali Sinha
Swathi Suresh
Graduate Research Assistant
Kosuke Tanaka
Lunshi Tang
Research Technician
Kelly Wu
Research Technician
Yuchen Xie
Yuchen Xie
Data Scientist at Audible, Inc., Newark, NJ
Wudan Yan
Graduate Student
Ju Zhou

Achievements

  • Distinguished Investigator Award, Washington University School of Medicine (2010)
  • Searle Scholar Award (2005)
  • Howard Temin Award, National Cancer Institute (2003)

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Career Opportunities

Apply now

Get in Touch

Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Emily H. Cheng discloses the following relationships and financial interests:

  • ICEN Therapeutics
    Professional Services and Activities

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures